

Patient Organisation Agreement

This Patient Organisation Agreement has been drawn up and entered into as of 09 April 2021 by and between

CSL Behring AB, Box 712, 182 17 Danderyd, SWEDEN, Reg. no. 556530-1974

and

Henrik Balle Boysen Strandkærsvej 30, 1, 8700 Horsens, Denmark. Mail: hbb@haescan.org

1. Background

HAE Scandinavia focuses to improve quality of life and to support patients and their caregivers in Denmark, Sweden and Norway. The organisation is working to establish a stronger collaboration between different stakeholders within the HAE field to enable optimal treatment and management of HAE patients and to raise awareness of the disease. CSL Behring operate in the HAE field by improving treatment for patients. There is a common interest in improving HAE treatment and care and to drive advocacy for improved patient access to treatment and care.

2. Collaboration project

Henrik Balle Boysen is invited to Session 2 of this virtual meeting. The aim of this virtual get together meeting is for European patient leaders to have an exchange regarding priorities in HAE advocacy and opportunities for collaboration.

3. Finances

3.1 No remuneration is paid in this project.

4. Transparency

- 4.1 Both Parties consent to the contents of this Agreement being shared with a third party.
- 4.2 Both parties consent to this agreement or a summary thereof being published on the company website and reported to ENLI at the end of the year in accordance with § 3 of the Patient Organizations Code regulated by the Ethical Committee for the Pharmaceutical Industry, ENLI

5. Consultation, evaluation

- 5.1 Henrik Balle Boysen is the contact person in matters concerning this Agreement.
- 5.2 CSL Behring AB has appointed Helena Stensman as their contact person in matters concerning this Agreement.
- 5.3 After completion of the project, the Parties shall jointly evaluate the project and their collaboration.
- 6. Agreement period and early termination



- 6.1 This Agreement is valid from 23-04-21 until 23-04-21.
- 6.2 If either party fails to fulfil their obligations pursuant to this Agreement and adjustments have not been made within thirty (30) days of the party being requested in writing to do so, the other party will be entitled to terminate the Agreement immediately.

7. Ethical rules and law

- 7.1 Ethical rules and national law apply to this agreement.
- 7.2 Henrik Balle Boysen may not refer to or make any representation relating to CSL Behring or its products or the co-operation under this agreement without CSL Behring's prior written approval. Henrik Balle Boysen shall submit all proposed materials mentioning CSL Behring, or referring to CSL Behring's products, or the co-operation under this agreement, to CSL Behring for written approval prior to publication or use.

8. Disputes

If a dispute should arise in conjunction with this Agreement, the Parties shall primarily attempt to resolve it through negotiation. In the event that the Parties are unable to reach an accord within thirty (30) days of the initial request for negotiation, the dispute shall be resolved in a Swedish Court.

9. E-signature

The Agreement may be executed by means of wet ink signatures or by using electronic signatures. If the Agreement is signed using electronic signatures, in making proof of this Agreement, an electronic copy of the Agreement will suffice. The Parties undertake not to dispute the validity of the Agreement based on the signatures being electronic.

This Agreement has been drawn up and signed in two (2) identical originals, of which each party has received an original.

Malmö 210409 Place and Date: **CSL Behring AB**:

Helena Stensman

Name and title: Helena Stensman Scientific advisor, Nordic Region Horsens, 12/4-2021 Place and Date: **HAE Scandinavia:**

Name and title: Henrik Balle Boysen President HAE Scandinavia

DocuSigned by:

Place and Date: Danderyd Sweden, April 9, 2021 CSL Behring AB:

DocuSigned by

Name and title: Martin Tenlen General Manager Nordic